Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes

British Journal of Haematology

Volumn 135, Issue 2, 2006, Pages 201-209

  Lim, Zi Yi ^a   Ho, Aloysius Y L ^a   Ingram, Wendy ^a   Kenyon, Michelle ^a   Pearce, Laurence ^a   Czepulkowski, Barbara ^a   Devereux, Stephen ^a   Duarte, Rafael F ^a   Pagliuca, Antonio ^a   Mufti, Ghulam J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alemtuzumab; Allogeneic transplantation; Myelodysplastic syndromes; Reduced intensity conditioning; Volunteer unrelated donor

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN; FLUDARABINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DONOR; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; EPIDEMIOLOGIC METHODS; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE;

EID: 33748743266     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06272.x     Document Type: Article

References (32)

1. Alyea, E.P., Kim, H.T., Ho, V., Cutler, C., Gribben, J., DeAngelo, D.J., Lee, S.J., Windawi, S., Ritz, J., Stone, R.M., Antin, J.H. & Soiffer, R.J. (2005) Comparative outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood, 105, 1810-1814.
2. Anderson, J.E., Appelbaum, F.R., Fisher, L.D., Schoch, G., Shulman, H., Anasetti, C., Bensinger, W.I., Bryant, E., Buckner, C.D. & Doney, K. (1993) Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood, 82, 677-681
3. Arnold, R., de, Witte, T., van Biezen, A., Hermans, J., Jacobsen, N., Runde, V., Gratwohl, A. & Apperley, J.F. (1998) Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplantation, 21, 1213-1216.
4. Aul, C., Gattermann, N. & Schneider, W. (1992) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. British Journal of Haematology, 82, 358.
5. Cahn, J.Y., Labopin, M., Schattenberg, A., Reiffers, J., Willemze, R., Zittoun, R., Bacigalupo, A., Prentice, G., Gluckman, E., Herve, P., Gratwohl, A. & Gorin, N.C. (1997) Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years: acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia, 11, 416.
6. Castro-Malaspina, H., Harris, R.E., Gajewski, J., Ramsay, N., Collins, R., Dharan, B., King, R. & Deeg, H.J. (2002) Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood, 99, 1943-1951.
7. Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., Mahendra, P., Craddock, C., Parker, A., Hunter, A., Hale, G., Waldmann, H., Williams, C.D., Yong, K., Linch, D.C., Goldstone, A.H. & Mackinnon, S. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen. Blood, 99, 1071-1078
8. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases, 40, 373-383
9. Cutler, C.S., Lee, S.J., Greenberg, P., Deeg, H.J., Perez, W.S., Anasetti, C., Bolwell, B.J., Cairo, M.S., Gale, R.P., Klein, J.P., Lazarus, H.M., Liesveld, J.L., McCarthy, P.L., Milone, G.A., Rizzo, J.D., Schultz, K.R., Trigg, M.E., Keating, A., Weisdorf, D.J., Antin, J.H. & Horowitz, M.M. (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 104, 579-585
10. Faulkner, R.D., Craddock, C., Byrne, J.L., Mahendra, P., Haynes, A.P., Prentice, H.G., Potter, M., Pagliuca, A., Ho, A., Devereux, S., McQuaker, G., Mufti, G., Yin, J.L. & Russell, N.H. (2004) BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 103, 428-434.
11. Flomenberg, N., Baxter-Lowe, L.A., Confer, D., Fernandez-Vina, M., Filipovich, A., Horowitz, M., Hurley, C., Kollman, C., Anasetti, C., Noreen, H., Begovich, A., Hildebrand, W., Petersdorf, E., Schmeckpeper, B., Setterholm, M., Trachtenberg, E., Williams, T., Yunis, E. & Weisdorf, D. (2004) Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood, 104, 1923-1930.
12. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
13. Ho, A.Y., Pagliuca, A., Kenyon, M., Parker, J.E., Mijovic, A., Devereux, S. & Mufti, G.J. (2004) Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood, 104, 1616-1623.
14. Howe, R.B., Porwit-MacDonald, A., Wanat, R., Tehranchi, R. & Hellstrom-Lindberg, E. (2004) The WHO classification of MDS does make a difference. Blood, 103, 3265-3270.
15. Jaffe, E.H.N., Stein, H. & Vardiman, J.W. (2001) The Myelodysplastic Syndromes. In: World Health Organisation classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. (Ed. by E.H.N. Jaffe, H. Stein & J.W. Vardiman), pp. 61-74. IARC Press, Lyon.
16. Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J.C., Schey, S., Mahendra, P., Morgan, G.J., Hale, G., Waldmann, H., de Elvira, M.C., Williams, C.D., Devereux, S., Linch, D.C., Goldstone, A.H. & Mackinnon, S. (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Blood, 96, 2419-2425.
17. Malcovati, L., Porta, M.G., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., Lazzarino, M. & Cazzola, M. (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology, 23, 7594-7603.
18. McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molina, A.J., Maloney, D.G., Chauncey, T.R., Gooley, T.A., Hegenbart, U., Nash, R.A., Radich, J., Wagner, J.L., Minor, S., Appelbaum, F.R., Bensinger, W.I., Bryant, E., Flowers, M.E., Georges, G.E., Grumet, F.C., Kiem, H.P., Torok-Storb, B., Yu, C., Blume, K.G. & Storb, R.F. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 97, 3390-3400.
19. Nevill, T.J., Fung, H.C., Shepherd, J.D., Horsman, D.E., Nantel, S.H., Klingemann, H.G., Forrest, D.L., Toze, C.L., Sutherland, H.J., Hogge, D.E., Naiman, S.C., Le, A., Brockington, D.A. & Barnett, M.J. (1998) Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood, 92, 1910-1917.
20. Sayer, H.G., Kroger, M., Beyer, J., Kiehl, M., Klein, S.A., Schaefer-Eckart, K., Schwerdtfeger, R., Siegert, W., Runde, V., Theuser, C., Martin, H., Schetelig, J., Beelen, D.W., Fauser, A., Kienast, J., Hoffken, K., Ehninger, G. & Bornhauser, M. (2003) Cooperative German Transplant Study Group. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplantation, 31, 1089-1095.
21. Schmid, C., Schleuning, M., Ledderose, G., Tischer, J. & Kolb, H.J. (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Journal of Clinical Oncology, 23, 5675-5687.
22. Schmid, C., Schleuning, M., Schwerdtfeger, R., Hertenstein, B., Mischak-Weissinger, E., Bunjes, D., Harsdorf, S.V., Scheid, C., Holtick, U., Greinix, H., Keil, F., Schneider, B., Sandherr, M., Bug, G., Tischer, J., Ledderose, G., Hallek, M., Hiddemann, W. & Kolb, H.J. (2006) Long term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced intensity conditioning for allogeneic stem cell transplantation. Blood, 108, 1092-1099.
23. Shimoni, A., Kroger, N., Zabelina, T., Ayuk, F., Hardan, I., Yeshurun, M., Shem-Tov, N., Avigdor, A, Ben-Bassat, I, Zander, AR & Nagler, A. (2005) Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age > 55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia, 19, 7-12.
24. Shimoni, A., Hardan, I., Shem-Tov, N., Yeshurun, M., Yerushalmi, R., Avigdor, A., Ben-Bassat, I. & Nagler, A. (2006) Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia, 20, 322-328.
25. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. & Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood, 91, 756-763.
26. Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. & Storer, B. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 2912-2919.
27. Sullivan, K.M. (1999) Graft versus host disease. In: Hematopoietic Cell Transplantation. (Ed. by E.D. Thomas K.G. Blume & S.J. Forman), pp. 515-536. Blackwell Sciences, Malden, MA.
28. Sullivan, K.M., Agura, E., Anasetti, C., Appelbaum, F., Badger, C., Bearman, S., Erickson, K., Flowers, M., Hansen, J., Loughran, T., (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Seminars in Hematology, 28, 250-259.
29. Sutton, L., Chastang, C., Ribaud, P., Jouet, J.P., Kuentz, M., Attal, M., Reiffers, J., Tigaud, J.M., Rio, B., Dauriac, C., Legros, M., Dreyfus, F., Lioure, B., Troussard, X., Milpied, N., Witz, F., Oriol, P., Cahn, J.Y., Michallet, M., Gluckman, E., Ifrah, N., Pico, J.L., Vilmer, E. & Leblond, V. (1996) Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood, 88, 358-365
30. de Witte, T. (2000) Stem cell transplantation for patients with myelodysplastic syndrome and secondary leukemias. International Journal of Hematology, 72, 151-156.
31. de Witte, T., Hermans, J., Vossen, J., Bacigalupo, A., Meloni, G., Jacobsen, N., Ruutu, T., Ljungman, P., Gratwohl, A., Runde, V., Niederwieser, D., van Biezen, A., Devergie, A., Cornelissen, J., Jouet, J.P., Arnold, R. & Apperley, J. (2000) Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). British Journal of Haematology, 110, 620-630
32. Wong, R., Giralt, S.A., Martin, T., Couriel, D.R., Anagnostopoulos, A., Hosing, C., Andersson, B.S., Cano, P., Shahjahan, M., Ippoliti, C., Estey, E.H., McMannis, J., Gajewski, J.L., Champlin, R.E. & de Lima, M. (2003) Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood, 102, 3052-3059.